TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2722598
Drug: Fluosol-DA 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluosol-DA 20% infusion (8 mL/Kg, 6 infusions) + 100% oxygen breathing
Study: 2722598
Drug: Fluosol-DA 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluosol-DA 20% infusion (various dosages and infusions) + 100% oxygen breathing
Study: 2722598
Drug: Fluosol-DA 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluosol-DA 20% infusion
Study: 28595464
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (BAT) for 16 months
Study: 28595464
Drug: Continuous pharmacotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous pharmacotherapy (BAT off) for 8 months followed by BAT for 8 months
Study: 25281894
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (3 mg Bid)
Study: 25281894
Drug: Systemic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic methylprednisolone (40 mg Qd for three days, then 8 mg Bid)
Study: 21442135
Drug: Weekly 1‐hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 1‐hr training session including aerobic interval training, circuit training, and whole body vibration
Study: 10999783
Drug: Low isoflavone
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low isoflavone diet (1.00 mg/kg body wt/day, averaging 65 mg/day)
Study: 10999783
Drug: High isoflavone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High isoflavone diet (2.01 mg/kg body wt/day, averaging 130 mg/day)
Study: 10999783
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (0.13 mg/kg body wt/day, averaging 8 mg/day)
Study: 8852910
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b alone (10 million units/m2, three times weekly for 1 year)
Study: 8852910
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b after prednisone priming (10 million units/m2, three times weekly for 1 year)
Study: 8852910
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, n=9)
Study: 23758485
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate once-daily (QD; 900 mg)
Study: 23758485
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate twice-daily (BID; 450 mg)
Study: 23758485
Drug: Oxcarbazepine BID
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine BID (450 mg)
Study: 19897177
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (18 or 24 IU)
Study: 14967872
Drug: Carbohydrate meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate meal (C; 3 g carbohydrate/kg)
Study: 14967872
Drug: Isoenergetic fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic fat meal (F; 1.3 g fat/kg)
Study: 9085972
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine with propofol
Study: 9085972
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin ointment with plain propofol
Study: 9085972
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin ointment with propofol mixed with lidocaine
Study: 8458683
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg, product A)
Study: 8458683
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg, product B)
Study: 30439316
Drug: Progressive early
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive early bed physical activity (15-30 minutes, twice a day)
Study: 30439316
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression (IPC) (30 minutes, twice a day)
Study: 18345549
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of physiological saline (placebo)
Study: 16943455
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (50 mg/day)
Study: 14689793
Drug: Mairin-P (isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mairin-P (isoniazid 60 mg, rifampicin 120 mg, pyrazinamide 300 mg, ethambutol hydrochloride 225 mg)
Study: 14689793
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment regimens with antituberculous drugs
Study: 3100871
Drug: Flutamide +
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide + LHRH agonist [D‐Trp6]LHRH ethylamide
Study: 3100871
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Flutamide + LHRH agonist)
Study: 22071882
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg and 1.25 mg
Study: 15896421
Drug: Enteral solution
Normalized name: GASTROENTERAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral solution of arginine
Study: 15896421
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution of amino-acids
Study: 11447774
Drug: Occlusive calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusive calcipotriol 50 micrograms/mg ointment applied twice-weekly overnight under occlusion
Study: 11447774
Drug: Nonocclusive calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonocclusive calcipotriol 50 micrograms/mg ointment applied twice-daily
Study: 9746766
Drug: Low-dose 6-methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 6-methylprednisolone (6MPred; 2 mg/kg/d; n = 47)
Study: 9746766
Drug: High-dose 6-methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 6-methylprednisolone (6MPred; 10 mg/kg/d; n = 48)
Study: 9746766
Drug: Low-dose 6-methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 6-methylprednisolone (6MPred; 2 mg/kg/d; switched to high-dose after 5 days)
Study: 9746766
Drug: Low-dose 6-methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 6-methylprednisolone (6MPred; 2 mg/kg/d; continued with tapering doses)
Study: 3167248
Drug: Conjoint Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint Therapy (8 sessions)
Study: 18849028
Drug: L-arginine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (20 mg/min) and tetrahydrobiopterin (BH(4)) (500 microg/min)
Study: 18849028
Drug: L-arginine and
Normalized name: Amino Acid, Amino Acids 5% (L-Arginine and L-Lysine) intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine and BH(4) infusion
Study: 16202894
Drug: Heparin-bonded cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded cardiopulmonary bypass circuits (HBCPB)
Study: 12376201
Drug: Anastrozole alone
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole alone or in combination with tamoxifen
Study: 10411413
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg/day with an oral contraceptive
Study: 10411413
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive
Study: 10411413
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg twice a day
Study: 2185691
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg every 12 h)
Study: 2185691
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg every 12 h) and oral rifampin (300 mg every 12 h)
Study: 84900
Drug: 3% acycloguanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% acycloguanosine eye ointment
Study: 84900
Drug: Topical acycloguanosine
Normalized name: Acycloguanosine
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical acycloguanosine alone
Study: 26345602
Drug: ALA (600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA (600 mg qd)
Study: 21250901
Drug: MVM+D (multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVM+D (multivitamin and mineral supplement plus vitamin D 1,200 IU/day)
Study: 21250901
Drug: MVM (multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVM (multivitamin and mineral supplement)
Study: 19625236
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered antidiabetic drugs (OADs) combination therapies
Study: 19625236
Drug: Single-tablet OAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tablet OAD combinations
Study: 7978472
Drug: Ropivacaine (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (0.25% plain solution, 140 mg, 56 ml)
Study: 7978472
Drug: Bupivacaine (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.25% plain solution, 140 mg, 56 ml)
Study: 30835573
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of bevacizumab
Study: 30835573
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of triamcinolone acetonide (TAC)
Study: 31313296
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily with water
Study: 31313296
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg with 250 mL of Coca-Cola
Study: 31313296
Drug: Sofosbuvir/velpatasvir (SOF/VEL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir/velpatasvir (SOF/VEL) 400/100 mg alone (reference)
Study: 23393319
Drug: In-center daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-center daily hemodialysis (6 days per week)
Study: 23393319
Drug: Daily hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hemodialysis (6 days per week)
Study: 18359280
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg dose of methylprednisolone (Group I)
Study: 18359280
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg dose of methylprednisolone (Group II)
Study: 18359280
Drug: four 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: four 250 mg doses of methylprednisolone (Group III)
Study: 18359280
Drug: four 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: four 500 mg doses of methylprednisolone (Group IV)
Study: 17324243
Drug: Desloratadine syrup
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine syrup 0.625 mg (1.25 ml) for children aged > or =6 months to <1 year
Study: 17324243
Drug: Desloratadine syrup
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine syrup 1.25 mg (2.5 ml) for children aged > or =1 year to < or =2 years
Study: 17324243
Drug: Desloratadine syrup
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine syrup 5 mg for adults
Study: 17324243
Drug: Doses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of 1.0 mg for children aged > or =6 months to <1 year and 1.25 mg for children aged > or =1 year to < or =2 years
Study: 14655041
Drug: ramosetron 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramosetron 300 microg plus dexamethasone 20 mg
Study: 14655041
Drug: ramosetron 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramosetron 100 microg once daily plus dexamethasone 8 mg twice daily
Study: 14655041
Drug: ramosetron 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramosetron 100 microg once daily
Study: 9700710
Drug: Monthly fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly fast fluid attenuated inversion recovery (FLAIR) scans associated with enhanced MRI after the injection of a triple dose (TD) of gadolinium (Gd)
Study: 9700710
Drug: Monthly dual‐echo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dual‐echo spin‐echo (SE) and enhanced magnetic resonance imaging (MRI) after the injection of a standard dose (SD) of gadolinium (Gd)
Study: 7924370
Drug: 1% l-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% l-epinephrine
Study: 2572260
Drug: Atenolol (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (a selective beta 1‐adrenoceptor antagonist)
Study: 2572260
Drug: Xamoterol (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (a beta 1‐adrenoceptor partial agonist with 43% agonist activity)
Study: 23601909
Drug: Physiological buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological buffered saline solution (Group 4)
Study: 21843921
Drug: Neoadjuvant trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant trastuzumab plus chemotherapy
Study: 15001604
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein supplement (0.75 g/kg)
Study: 15001604
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein supplement (0.04 g/kg)
Study: 15273093
Drug: Topical nitrogen
Normalized name: nitrogen Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitrogen oxides (sodium nitrite 6%, citric acid monohydrate 9%) applied daily for 6 weeks
Study: 15273093
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied daily for 6 weeks
Study: 15273093
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received nitrogen oxide-generating creams for the second 6 weeks
Study: 10994918
Drug: Carbohydrate drink
Normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate drink (16 mL x kg(‐1) of a drink containing 7.6 g x 100 mL(‐1) carbohydrate)
Study: 1287378
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock (HPL)
Study: 3546153
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg (single oral dose)
Study: 3546153
Drug: Ofloxacin 300
Normalized name: ofloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 300 mg b.i.d. (seven-day course)
Study: 3546153
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg b.i.d. (seven-day course)
Study: 2899536
Drug: sulphasalazine 2
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulphasalazine 2 g daily
Study: 2899536
Drug: mesalazine 800
Normalized name: mesalazine 800 MG Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine 800 mg daily
Study: 2899536
Drug: mesalazine 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine 2.4 g daily
Study: 26517214
Drug: bromazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromazepam (6 mg)
Study: 26517214
Drug: modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: modafinil (200 mg)
Study: 21996071
Drug: Tape-OCA combination
Normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tape-OCA combination
Study: 17399972
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg inhalation
Study: 16132321
Drug: celecoxib, 200
Normalized name: Celecoxib, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib, 200 mg by mouth
Study: 16132321
Drug: rofecoxib, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rofecoxib, 50 mg by mouth
Study: 16132321
Drug: diclophenac sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclophenac sodium, 75 mg intramuscularly
Study: 16132321
Drug: placebo, pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, pill
Study: 3128114
Drug: Cefoxitin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (multiple 2 gm doses)
Study: 23090004
Drug: Risperidone +
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone + Ulinastatin (Risperidone 1 mg orally 30-60 min before ERCP, Ulinastatin 150000 U intravenously for 10 min prior to ERCP)
Study: 21084763
Drug: Linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (5 mg/day × 6 days)
Study: 21084763
Drug: Glyburide (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (1.75 mg/day × 1 day)
Study: 16415641
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy with fibrinolytic agents
Study: 15383186
Drug: Oral propionyl-L-carnitine
Normalized name: glycine propionyl-L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propionyl-L-carnitine (PLC) 2 g/day plus sildenafil 50 mg twice weekly (Group 1)
Study: 9558831
Drug: Control (vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (vaccine only, no OMT)
Study: 21341146
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block with 0.5% levobupivacaine (30 mL) followed by interscalene infusion: 0.125% levobupivacaine 5 mL/h basal infusion, 5 mL bolus dose, 20 min lockout time.
Study: 21341146
Drug: Subacromial infusion:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial infusion: 0.125% levobupivacaine 5 mL/h basal infusion, 5 mL bolus dose, 20 min lockout time.
Study: 19639303
Drug: Broad Spectrum
Normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Broad Spectrum Treatment (BST) with extended Naltrexone (NTX)
Study: 19639303
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET) with extended Naltrexone (NTX)
Study: 19639303
Drug: Broad Spectrum
Normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Broad Spectrum Treatment (BST) with short Naltrexone (NTX)
Study: 19639303
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET) with short Naltrexone (NTX)
Study: 6652642
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after initial treatment
Study: 11783837
Drug: Amitryptiline, ondansetron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitryptiline, ondansetron, zoldipem, growth hormone
Study: 11783837
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs, malic acid with magnesium, calcitonin injections, s-adenyl-L-methionine
Study: 9131679
Drug: 20% long‐chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% long‐chain triacylglycerols (LCT) with 55% of linoleic acid and 7% of alpha linolenic acid in 100 g of emulsion
Study: 9131679
Drug: 20% medium‐chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% medium‐chain triacyglycerols (MCT) and LCT with 26% of linoleic acid and 4% of alpha linolenic acid in 100 g of emulsion
Study: 8198026
Drug: Low-density lipoprotein
Normalized name: Low-density lipoprotein receptor kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-density lipoprotein (LDL) apheresis with a dextran sulfate cellulose column; pravastatin 10 mg and niacin 1,500 mg daily for some patients.
Study: 3283916
Drug: Maintenance ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance ranitidine therapy (150 mg at night)
Study: 20372175
Drug: Low EGCG
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low EGCG (300 mg)
Study: 20372175
Drug: High EGCG
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High EGCG (600 mg)
Study: 20372175
Drug: EGCG/Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG/Caffeine (300 mg/200 mg)
Study: 10473894
Drug: Doxapram (0.5‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (0.5‐2 mg/kg/h intravenously or 2‐8 mg/kg every 2 h orally)
Study: 9772585
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Western and traditional Chinese medicine (Astragalus membranaceus, taurine, coenzyme Q10, antiarrhythmics)
Study: 9772585
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (glucose‐insulin‐potassium (GIK), coenzyme Q10, antiarrhythmics)
Study: 24979303
Drug: LDL-C target
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C target A (2.8-1.8 mmol/l)
Study: 24979303
Drug: LDL-C target
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C target B (<1.8 mmol/l)